Skip to content

Screening of Oral Human Papillomavirus (HPV)

Prevalence of Oral Human Papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma (OSCC) among patients attending a tertiary care center in Mangalore - A prospective study. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/04/064991
Enrollment
120
Registered
2024-04-01
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B977- Papillomavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Since it is an observational study the answer is Nil: Nil

Sponsors

Manipal Institute of Virology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: I. Patients above the age of 18 years with class III/IV oral cancer II. Patients who have to undergo surgery for the removal of tumors III. Patients complying to provide consent for the study.

Exclusion criteria

Exclusion criteria: I. Oral cancer patients not undergoing surgery for removal of tumors II. Patients not willing to give consent for the study.

Design outcomes

Primary

MeasureTime frame
1. To assess the oral HPV prevalence among OSCC patients. This is crucial for devising appropriate strategies and for identifying highrisk groups that require targeted interventions. 2. Study will help in the identification of other high-risk HPV among OSCC patients. 3. The study will also explore saliva testing as a strategy for testing oral HPV among cancer population 4. The study is also aimed to identify the impact of different risk factors associated with OSCC. 5. Study will provide insights regarding mutational status of E6 and E7 oncogenes. Timepoint: 6 Months

Secondary

MeasureTime frame
4. The study is also aimed to identify the impact of different risk factors associated with OSCC. 5. Study will provide insights regarding mutational status of E6 and E7 oncogenes. Timepoint: 12 Months

Countries

India

Contacts

Public ContactDr Anitha J

Manipal Academy of Higher Education

anitha.j@manipal.edu08202922663

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026